Clinical trial
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and…
NCT00419536 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00419536 |
|---|---|
| Title | Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone |
| Official title | A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hormone Refractory Prostate Cancer Disease |
| Intervention type | Drug |
| Interventions | LBH589 |
| Enrollment | 108 |
| Start date | May 1, 2006 |
| First posted | Jan 8, 2007 |
| Last update posted | Apr 8, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: